Market Closed -
23:00:00 11/09/2026 +03
5-day change
1st Jan Change
106.20 USD
+2.83%
-4.24%
+848.76%
Market Cap
42.24M
36.4M
34.46M
31.24M
58.6M
4.04B
58.9M
409M
157M
2.05B
159M
155M
6.49B
P/E 2021
-3.42x
P/E 2022
-0.31x Enterprise Value
-39.84M
-34.32M
-32.5M
-29.46M
-55.26M
-3.81B
-55.54M
-386M
-148M
-1.94B
-150M
-146M
-6.12B
EV / Sales 2021
-
EV / Sales 2022
-
Free-Float
-
Yield 2021 *
-
Yield 2022
-
5 minutes 15 minutes 30 minutes Hour Day Week Month
Close Mountain
11/09/23
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index
CI
11/09/23
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
CI
03/08/23
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
23/06/23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index
CI
23/06/23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index
CI
23/06/23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index
CI
23/06/23
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index
CI
19/05/23
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer
CI
15/05/23
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
03/05/23
Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
03/05/23
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.
CI
06/04/23
Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc
CI
28/02/23
HC Wainwright Initiates Magenta Therapeutics at Neutral
MT
11/09/23
Adrenoleukodystrophy Clinical Trials, and Key Companies|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
AQ
07/08/23
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
BU
04/05/23
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
BU
03/05/23
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
03/05/23
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
AQ
1 day +2.83%
Current month +848.76%
Current year +848.76%
5 years
5.14
135.84
10 years
5.14
336
2021 2022 Net sales
-
-
Net income
-71.14M
-61.29M
-58.03M
-52.6M
-98.68M
-6.8B
-99.18M
-689M
-265M
-3.46B
-267M
-261M
-10.93B
-76.46M
-65.88M
-62.38M
-56.54M
-106M
-7.3B
-107M
-741M
-285M
-3.72B
-287M
-281M
-11.74B
Net Debt
-177M
-152M
-144M
-131M
-245M
-16.9B
-247M
-1.71B
-659M
-8.6B
-664M
-650M
-27.17B
-82.08M
-70.72M
-66.96M
-60.69M
-114M
-7.84B
-114M
-795M
-306M
-3.99B
-308M
-301M
-12.61B
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Date
Price
Change
11/09/26
$106.20
+2.83%
10/09/26
$103.28
-3.51%
09/09/26
$107.04
-1.92%
08/09/26
$109.13
+0.95%
04/09/26
$108.10
+0.23%
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
Select your edition
All financial news and data tailored to specific country editions
Deutsche Boerse AG
